Parkinson's Disease Trial, Not Yet Recruiting NCT07105280 Sponsor: HagaZiekenhuis Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Not Yet Recruiting

NCT07105280
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People diagnosed with Parkinson's disease who have deep brain stimulation (DBS) devices placed on both sides of the brain in a specific brain region called the subthalamic nucleus (STN).
  • People who had their current DBS system (the Percept™ PC or RC device) implanted at least 6 months ago.
  • People who still experience symptoms such as difficulty speaking, episodes of freezing (sudden inability to move), or unpredictable "on-off" periods where their medication stops working well enough.
  • People whose DBS device is producing a usable brain signal (called an LFP signal) on at least one side of the brain.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose treating doctor considers it clinically unsafe or unreliable for them to switch to the new type of DBS, use the device's remote control on their own, or attend regular clinic visits — for example, due to active or unstable cognitive or mental health conditions.
  • People whose DBS electrodes have high resistance, are faulty, or produce insufficient brain signal quality, or where stimulation is mainly delivered through the outermost contact points on both sides in a way that would prevent the new DBS approach from working properly (confirm with trial site).
  • People who have previously objected to their medical records being used for medical research purposes.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Maria Fiorella Contarino, MD, PhD, HagaZiekenhuis

Phone: +31 (0)70 210 2997

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
HagaZiekenhuis
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
1 June 2027

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Patient preference of DBS settings

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov